Sponsor or institution

Clinical trials and research at Akeso

• 39Clinical trials
• 5Countries

Newest trials

All recruiting trials (39)

• AK157D1 injection for advanced solid tumors

  A first-in-human Phase 1 study tests AK157D1 injection in adults with unresectable advanced solid tumors to see if it is safe and tolerable and to get early signs of how it behaves in the body and against tumors.

  Recruiting Phase 1 Akeso · Harbin, Heilongjiang and 2 other locations · NCT07847281

• Cadonilimab with chemotherapy vs chemotherapy with/without nivolumab as first-line treatment for HER2-negative advanced gastric/GEJ cancer

  This study tests whether adding cadonilimab to chemotherapy helps people with newly diagnosed, unresectable or metastatic HER2-negative gastric/GEJ cancer live longer, compared with standard chemo alone (with or without nivolumab).

  Recruiting Phase 3 Akeso · Phoenix, Arizona and 24 other locations · NCT07700979

• A Phase II test of AK146D1 with AK112 in advanced NSCLC

  This phase II study tests whether AK146D1 together with AK112 or other cancer therapies can be safely given and help treat adults with advanced non-small cell lung cancer.

  Recruiting Phase 2 Akeso · Guangzhou, Guangdong · NCT07669779

• AK138D1 alone or with Ivonescimab in advanced non-small cell lung cancer

  This study tests AK138D1 by itself or with Ivonescimab in adults with advanced non-small cell lung cancer to see if it is safe and can help shrink tumors.

  Recruiting Phase 1/2 Akeso · Shanghai, Shanghai Municipality · NCT07623356

• AK146D1 plus AK112 in advanced breast cancer

  This phase II study tests AK146D1 with AK112 to see if they are safe and can help shrink or control tumors in adults with advanced, HER2-negative breast cancer.

  Recruiting Phase 2 Akeso · Shanghai, Shanghai Municipality · NCT07591090

• Long-term follow-up after cadonilimab (AK104) treatment

  This follow-up collects long-term health and survival information from people with advanced gastric cancer who previously received cadonilimab (AK104) in earlier clinical trials.

  Recruiting Akeso · Beijing · NCT07547787

• Neoadjuvant and adjuvant AK104 for resectable MSI-H/dMMR colon cancer

  This phase 3 trial will test whether giving the antibody AK104 before and after surgery works better than standard adjuvant chemotherapy for adults with resectable MSI‑H or dMMR colon cancer.

  Recruiting Phase 3 Akeso · Guangzhou · NCT07412613

• AK138D1 for advanced solid tumors

  We will try AK138D1 given by IV in adults with advanced solid tumors that haven't responded to standard treatments to find a safe dose and see if it can shrink tumors.

  Recruiting Phase 1 Akeso · Harbin, Heilongjiang · NCT07281326

• Perioperative cadonilimab plus neoadjuvant chemotherapy for resectable thoracic esophageal squamous cell carcinoma

  This trial will test whether adding cadonilimab to pre-surgery cisplatin/paclitaxel chemotherapy helps people with resectable esophageal squamous cell carcinoma have better outcomes.

  Recruiting Phase 2 Akeso · Xi'an · NCT07263919

• Ivonescimab combinations for first-line extensive-stage small cell lung cancer

  This test tries whether adding AK117 or cadonilimab to ivonescimab plus chemotherapy helps adults newly diagnosed with extensive-stage small cell lung cancer.

  Recruiting at 2 sites Phase 2 Akeso · Beijing, Beijing Municipality and 2 other locations · NCT07245446

• AK130 combined with AK112 for advanced pancreatic cancer

  This phase II test looks at whether combining AK130 with AK112, or giving AK112 alone, can help people with advanced pancreatic cancer who have progressed after up to two prior systemic therapies.

  Recruiting at 2 sites Phase 2 Akeso · Shanghai, Shanghai Municipality and 1 other locations · NCT07114315

• AK146D1 injection for advanced solid tumors.

  This will test whether AK146D1 injection is safe and shows early anti-tumor activity in adults with advanced solid tumors who have progressed on or cannot receive standard treatments.

  Recruiting Phase 1 Akeso · Guangzhou, Guangdong · NCT07067567

• AK104 or AK112 plus TT-00420 for advanced hepatocellular carcinoma

  This study tests whether combining AK104 or AK112 with the oral drug TT-00420 (tinengotinib) can help adults with advanced hepatocellular carcinoma (HCC).

  Recruiting Phase 2 Akeso · Wuhan, China · NCT07052253

• Cadonilimab with SOX chemotherapy given before and after surgery for removable stomach or gastroesophageal junction cancer

  This tests whether adding cadonilimab to SOX chemotherapy before and after surgery helps people with resectable stomach or gastroesophageal junction adenocarcinoma.

  Recruiting at 6 sites Phase 3 Akeso · Beijing, Beijing Municipality and 5 other locations · NCT07023315

• AK112 consolidation therapy for limited-stage small cell lung cancer after concurrent chemoradiation

  This trial will test whether the experimental antibody AK112 (ivonescimab) given after successful concurrent chemoradiation can help prevent recurrence in adults with limited-stage small cell lung cancer.

  Recruiting at 52 sites Phase 3 Akeso · Beijing, Beijing Municipality and 52 other locations · NCT07010263

• Ivonescimab plus chemotherapy, with or without AK117, for metastatic pancreatic cancer

  This trial will test whether adding the antibody Ivonescimab, with or without AK117, to standard chemotherapy helps people with metastatic pancreatic cancer live longer or have better tumor responses.

  Recruiting at 3 sites Phase 3 Akeso · Harbin, Heilongjiang and 2 other locations · NCT06953999

• AK112 plus chemotherapy versus bevacizumab plus chemotherapy for first-line metastatic colorectal cancer

  This tests whether adding AK112 to standard chemotherapy works better than bevacizumab plus chemotherapy as the first treatment for people with metastatic colorectal cancer.

  Recruiting at 2 sites Phase 3 Akeso · Guanzhou, Guangdong and 1 other locations · NCT06951503

• AK129 combination therapy for advanced solid tumors

  This study tests AK129 given with chemotherapy in adults with advanced non-small cell lung, head and neck, or colorectal cancers to find a safe dose and see if it helps control their disease.

  Recruiting Phase 1/2 Akeso · Shenyang, Liaoning · NCT06943820

• AK130 with AK112 for advanced biliary tract cancer

  This trial will test whether combining AK130 with AK112, or using AK112 alone, is safe and helps people with advanced biliary tract cancer who have not responded to first-line therapy.

  Recruiting Phase 1/2 Akeso · Beijing, Beijing Municipality · NCT06938321

• AK146D1 injection for adults with advanced solid tumors

  This trial will try an experimental injection called AK146D1 in adults with advanced solid tumors that have progressed after standard treatment.

  Recruiting Phase 1 Akeso · Sydney, New South Wales · NCT06929663

• Ivonescimab plus docetaxel for advanced non-small cell lung cancer

  This trial tests whether adding ivonescimab to docetaxel helps people with advanced or metastatic non-small cell lung cancer that progressed after PD-(L)1 inhibitor therapy.

  Recruiting Phase 3 Akeso · Shanghai, Shanghai Municipality · NCT06928389

• AK112 plus nab‑paclitaxel versus placebo plus nab‑paclitaxel for first‑line inoperable or metastatic triple‑negative breast cancer

  This trial tests whether adding AK112 to nab‑paclitaxel works better than placebo plus nab‑paclitaxel as first‑line treatment for adults with inoperable locally advanced or metastatic triple‑negative breast cancer.

  Recruiting Phase 3 Akeso · Beijing · NCT06767527

• Testing AK138D1 for advanced solid tumors

  This study is testing a new treatment called AK138D1 to see if it is safe and effective for people with advanced solid tumors.

  Recruiting at 2 sites Phase 1 Akeso · Blacktown, New South Wales and 3 other locations · NCT06730386

• Combining AK112 with chemotherapy and Olaparib for ovarian cancer treatment

  This study is testing if a new drug called AK112, when combined with chemotherapy and Olaparib, can help women with certain types of ovarian cancer feel better and improve their treatment outcomes.

  Recruiting Phase 2 Akeso · Wuhan · NCT06686030

• Evaluating AK129 with or without AK117 for patients with resistant Classic Hodgkin Lymphoma

  This study is testing if a new treatment called AK129, alone or with another drug AK117, can help adults with tough-to-treat classic Hodgkin lymphoma feel better after other treatments have failed.

  Recruiting Phase 1/2 Akeso · Beijing · NCT06642792

• Comparing AK104 and Sugemalimab for advanced lung cancer treatment

  This study is testing whether a new treatment called AK104 works better than Sugemalimab for people with advanced lung cancer who haven't seen their disease get worse after chemotherapy and radiation.

  Recruiting Phase 3 Akeso · Jinan · NCT06617416

• Comparing AK112 and AK117 to Pembrolizumab for Head and Neck Cancer

  This study is testing if a new combination treatment of AK112 and AK117 can work better than the standard drug pembrolizumab for people with advanced head and neck cancer.

  Recruiting at 2 sites Phase 3 Akeso · Wuhan, Hubei and 1 other locations · NCT06601335

• Combination therapy for recurrent ovarian cancer

  This study is testing a new combination of treatments for women with recurrent ovarian cancer to see if it can help them feel better and improve their outcomes.

  Recruiting Phase 2 Akeso · Shanghai · NCT06560112

• AK112 with other therapies for advanced liver cancer

  This trial will test AK112 alone or with other cancer drugs to see if it is safe and helps people with advanced hepatocellular carcinoma.

  Recruiting at 2 sites Phase 1/2 Akeso · Beijing, Beijing Municipality and 1 other locations · NCT06530251

• Combining AK104 and Lenvatinib with TACE for treating liver cancer

  This study is testing if combining two treatments, AK104 and lenvatinib, with a procedure called TACE can help people with liver cancer who can't have surgery feel better compared to just having TACE alone.

  Recruiting at 4 sites Phase 3 Akeso · Zhengzhou, Henan and 3 other locations · NCT06371157

• Combination treatment for advanced gastric cancer

  This study is testing a new combination of treatments for advanced stomach cancer to see if it works better than the standard treatment for patients who haven't responded to earlier therapies.

  Recruiting Phase 3 Akeso · Beijing · NCT06341335

• Evaluating AK117 with Azacitidine for higher-risk Myelodysplastic Syndromes

  This study is testing if a new treatment combining AK117 with azacitidine can help people recently diagnosed with higher-risk myelodysplastic syndromes feel better compared to standard treatment.

  Recruiting at 15 sites Phase 2 Akeso · Los Angeles, California and 14 other locations · NCT06196203

• Evaluating AK131 for advanced solid tumors

  This study is testing a new treatment called AK131 to see if it can help people with advanced solid tumors that haven't responded to other therapies.

  Recruiting Phase 1 Akeso · Jinan, Shandong · NCT06166888

• Combining cadonilimab with chemotherapy for gastric cancer treatment

  This study is testing if adding cadonilimab to chemotherapy can help people with stomach cancer before their surgery.

  Recruiting Phase 2 Akeso · Tianjin · NCT05960955

• Combining AK104 with chemotherapy for advanced pancreatic cancer treatment

  This study is testing a new treatment that combines a drug called AK104 with chemotherapy to see if it helps people with advanced pancreatic cancer who haven't had treatment before.

  Recruiting at 7 sites Phase 2 Akeso · Beijing, Beijing Municipality and 6 other locations · NCT05859750

• AK119 plus AK112 for advanced solid tumors

  This trial tests whether combining two experimental drugs, AK119 and AK112, is safe and may help adults with advanced solid tumors that have progressed after standard treatment.

  Recruiting Phase 1/2 Akeso · Beijing, Beijing Municipality · NCT05689853

• Using AK104 to prevent recurrence of liver cancer after surgery

  This study is testing if a new treatment called AK104 can help prevent liver cancer from coming back after surgery in patients who are at high risk.

  Recruiting Phase 3 Akeso · Shanghai, Shanghai Municipality · NCT05489289

• Combining AK109 and AK104 for advanced solid tumors

  This study is testing a new combination of two treatments, AK109 and AK104, to see if they can help people with advanced solid tumors that haven't responded to other therapies.

  Recruiting Phase 1/2 Akeso · Hangzhou, Zhejiang · NCT05142423

• Testing AK109 and AK104 for advanced stomach cancer treatment

  This study is testing two new treatments, AK109 and AK104, to see if they can help people with advanced stomach cancer who haven't had success with other therapies.

  Recruiting Phase 1/2 Akeso · Beijing · NCT04982276

Quick answers

How many clinical trials run by Akeso are recruiting right now?

39, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 5 countries. The most sites are in China (37 trials), United States (2 trials), Australia (2 trials), Germany (1 trial), Poland (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 13, Phase 2: 11, Phase 1/2: 8, Phase 1: 6. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →